Safely Prescribing Controlled Substances in Oncology - 2025
-
Register
- Non-member - $150
- Member - Free!
The Safely Prescribing Controlled Substances in Oncology modules by APSHO include 13 comprehensive, and self-paced modules, thoughtfully crafted to equip you with the knowledge and expertise necessary to safely prescribe controlled substances and to understand and manage substance use disorders in the hematology/oncology setting. (These modules will meet the DEA requirement for 8 hours of training on substance use disorder.) 9 CE-Accredited Hours (4.5 pharmacology hours for ANCC accreditation)
-
Contains 5 Component(s), Includes Credits
0.50 CE-Accredited Hours (0.25 pharmacology hours for ANCC accreditation)
- Define SUD based on accepted DSM-5 definition
- Articulate the impact of SUD on cancer outcomes
- Recognize the physical and psychosocial signs of SUD
-
Contains 5 Component(s), Includes Credits
0.75 CE-Accredited Hours (0.75 pharmacology hours for ANCC accreditation)
- Define risk/benefit ratio in opioid prescribing
- Discuss the spectrum of opioid use disorders
- Describe a plan of care to manage patients who exhibit signs of misuse, abuse, or diversion including the Compassion High Alert Team (CHAT) model and deprescribing practices
-
Contains 5 Component(s), Includes Credits
1.00 CE-Accredited Hours (0.75 pharmacology hours for ANCC accreditation)
- Recognize the interaction between stigma associated with SUD and overdose
- Identify harm reduction approaches
- Describe the use of naloxone in overdose
-
Contains 5 Component(s), Includes Credits
0.50 CE-Accredited Hours (0.00 pharmacology hours for ANCC accreditation)
- List barriers to effective communication with persons with substance use disorder
- Describe effective and practical communication techniques for providers treating persons with substance use disorder
- Describe effective engagement techniques for providers treating persons with substance use disorder
-
Contains 5 Component(s), Includes Credits
0.50 CE-Accredited Hours (0.50 pharmacology hours for ANCC accreditation)
At the conclusion of this activity, participants will be able to:
- Differentiate Substance Use Disorder (SUD) and Opioid Use Disorder (OUD)
- Describe the pharmacology of buprenorphine and its role in Medication Assisted Treatment (MAT) & Medications for Opioid Use Disorder (MOUD)
- Identify myths, misconceptions, and stigmas of Buprenorphine
-
Contains 5 Component(s), Includes Credits
1.00 CE-Accredited Hours (0.25 pharmacology hours for ANCC accreditation)
- Discuss substance use disorder stigma and how this can affect patient/caregiver education
- Describe key elements of patient assessment may guide the patient/caregiver educational plan
- List fundamental elements that should be included in the patient/caregiver educational plan
-
Contains 5 Component(s), Includes Credits
0.50 CE-Accredited Hours (0.00 pharmacology hours for ANCC accreditation)
- Describe elements of effective communication
- Identify barriers to effective communication
- Develop strategies to improve communication
-
Contains 5 Component(s), Includes Credits
0.75 CE-Accredited Hours (0.00 pharmacology hours for ANCC accreditation)
- Describe the frequency of trauma and the subsequent impact of trauma on patients’ health outcomes.
- List the six key principles of organizational trauma-informed care as identified by Substance Abuse and Mental Health Administration (SAMHSA).
- Name and briefly describe screening tools use to guide the practitioner in the need for referrals.
-
Contains 5 Component(s), Includes Credits
0.50 CE-Accredited Hours (0.25 pharmacology hours for ANCC accreditation)
- Define Substance Use Disorder (SUD)
- Recognize the importance of screening for SUD
- Review the most frequently used screening tools
-
Contains 5 Component(s), Includes Credits
1.00 CE-Accredited Hours (0.50 pharmacology hours for ANCC accreditation)
- Understand the impact of the opioid epidemic on prescribing controlled substances
- Describe the classification of controlled substances
- Define the educational needs and safe prescribing practices for controlled substances
